OpGen Corporate Overview

January 2020



Forward Looking Statements

This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our pending business combination transaction with Curetis GmbH ("Curetis"), a wholly owned subsidiary of Curetis N.V.; ongoing and planned product development by each of OpGen and Curetis; revenues, net loss from operations and cash burn of the combined company, the timing of, and ability to make, regulatory filings and obtain and maintain regulatory approvals for product candidates of OpGen and Curetis; expectations regarding product launch; our results of operations, cash needs, and spending of the proceeds from this offering, including the funds to be lent to Curetis; the financial condition, liquidity, prospects, growth and strategies of the combined company; the industry in which we and Curetis operate; and the trends that may affect the industry or us or the combined company.

We may, in some cases, use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully and timely seek approval of, and obtain approval of our stockholders for the business combination with Curetis, satisfy the closing conditions under the implementation agreement, successfully combine the businesses of OpGen and Curetis, comply with the complexities of a global business, achieve the synergies we expect and successfully implement the combined company's strategic and business goals and objectives. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review the factors described in the "Risk Factors" section of our Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC") on October 17, 2019, including the documents incorporated by reference therein. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events except to the extent required by applicable securities laws.

OPGEN CORPORATE OVERVIEW

Precision medicine company focused on combatting the global antibiotic resistance crisis by leveraging molecular diagnostics, informatics, and genomic analysis

Acuitas Lighthouse®

Provides rapid and actionable information about life threatening drug resistant infections

Building global network of customers and partners to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs

Acuitas® AMR Gene Panel

Key product Acuitas® AMR Gene Panel is designed to detect five pathogens and up to 47 resistance genes, predicting resistance for 9 classes of antibiotics

Collaborations with industry leaders to support the execution of our commercialization strategy as we work to address a $2 billion potential market for precision medicine MDRO solutions

OpGen®

CURETIS GROUP CORPORATE OVERVIEW

curetis

A commercial stage molecular diagnostics company striving molecular microbiology leadership through proprietary platforms and content

MDx platforms for low- to high-plex sample-to-answer PCR testing for a broad range of sample types relevant for molecular microbiology

Five CE-IVD-marked and 2 US-FDA cleared syndromic testing panels for major infectious disease indications in hospitalized patients

AMR data intelligence and biomarkers based on what Curetis believes to be the most comprehensive whole-genome knowledge base, ARESdb, on the genetics of antibiotic resistance

Direct sales channel in the U.S. complemented by a large network of distributors world-wide. Strategic partnerships for NGS and Bio-IT solutions for fighting AMR with key life science, IVD, and pharma players

OpGen

COMBINING TO BUILD A STRONGER FUTURE

Strategic Rationale

- Establish a leading antimicrobial resistance (AMR) precision medicine business
- Broad portfolio of high impact rapid diagnostics and AMR bioinformatics
- Leverage combined sales, distribution, bioinformatics and operating infrastructure

➢ **Combined company expected to be positioned for strong growth profile and sustained value creation**

Structure of Transaction

- OpGen acquisition of Curetis GmbH for 2.66 million new shares of OpGen common stock

TRANSACTION TIMELINE AND CONDITIONS TO CLOSING

Both companies' Boards of Directors have approved the implementation agreement

The transaction is expected to close following approval by shareholders and debt holders for both OpGen and Curetis.

Conditions to Closing

- ✓ Successful completion by OpGen of $10 million equity financing
- ✓ Supported by debt holders of Curetis N.V., Curetis GmbH, and OpGen, Inc.
- Both companies now seeking approval from their respective shareholders in meetings to be held on March 10, 2020

STRATEGIC BENEFITS

- Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection
- Proprietary molecular diagnostic tests and platforms
- Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics
- Global commercial channel capabilities & partners
- Financial leverage, operational synergies, and positive growth-driven business outlook

COMBINED COMPANY TO ADDRESS MULTIPLE HIGH IMPACT UNMET CLINICAL NEEDS AND LARGE AVAILABLE MARKET OPPORTUNITIES

U.S. and European market with high unmet medical need addressable through hospital-focused sales channels



- Pneumonia (HPN/LRT)
- Implant and Tissue Infections (ITI)
- Blood Culture (BCU)
- Intra-Abdominal Infections (IAI)
- Sepsis Host Response (SHR)
- Urinary Tract Infections (UTI)

curetis

OpGen curetis

The current Curetis portfolio and pipeline of cartridges according to Curetis management estimates target about 10 million patients annually in EU and U.S. with additional upside in Asia / Pacific and ROW markets

OpGen

1. OpGen estimates based upon information provided by Curetis

COMBINED COMPANY'S PORTFOLIO OF COMMERCIAL STAGE PRODUCTS & STRATEGIC RELATIONSHIPS

Unyvero Platform & Tests (Curetis)

Unyvero FDA-cleared platform and lower respiratory tract infection (LRT) test

Acuitas Tests & Acuitas Lighthouse (OpGen)

Acuitas tests in development and pending FDA clearance to improve antibiotic decision making

Acuitas® AMR Gene Panel

Acuitas Lighthouse®

Global Commercial Presence (Curetis)

Direct sales in U.S., European distribution with A. Menarini Diagnostics, China distribution with Beijing Clear Biotech

OpGen® curetis

ares genetics

Strategic Fit

Transformative Strategic Relationship in MDx and BioIT

STRATEGIC BENEFITS

- Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection
- Proprietary molecular diagnostic tests and platforms
- Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics
- Global commercial channel capabilities & partners
- Financial leverage, operational synergies, and positive growth-driven business outlook

SAMPLE-TO-ANSWER AND HIGH-THROUGHPUT TESTING CAPABILITIES

Molecular microbiology leadership through proprietary platforms and content

Striving for Molecular Microbiology Leadership

MDx Platforms	MDx Content
unyvero	Acuitas** AMR Gene Panel Acuitas Lighthouse®
	ares genetics a curetis group company 
Unyvero A50 High-Plex PCR	**AREScb** MDx Content & NGS Applications
	
Unyvero A30 *RQ** Low- to Mid-Plex PCR	
Low- to High-Plex PCR Broad Sample Range	Proprietary PCR & NGS Applications based on Leading AI-Powered AMR Knowledgebases

* Unyvero A30 *RQ* Analyzer in development, latest design concept; final product may differ

**Pending 510(k), not for diagnostic use.

OpGen®

CURRENT AND NEAR-TERM U.S. PRODUCT OFFERINGS

Curetis Unyvero Pneumonia (LRT / LRT BAL)

Description:
- Sample-to-answer multiplex PCR from native specimen in about 5 hours with ~2min hands-on time
- 19 / 20 multiplexed PCR assays covering 36 / 37 Pathogen ID, 10 resistance genes

Status:
- LRT FDA-cleared (*De Novo 510(k)*) April ’18, launched June ’18
- *LRT BAL FDA cleared (510(k)) in Dec 2019*

Differentiators:
- Most comprehensive panel specifically tailored to bacterial pneumonia delivering unique clinically actionable insights

Coming Next:
- **Unyvero LRT plus high sensitivity application for BAL samples. 510(k) cleared December 2019**
- **Launch of LRT BAL in USA in Q1-2020**

OpGen Acuitas AMR Gene Panel

Description:
- Sample-to-answer multiplex PCR from bacterial isolates in <3 hours
- Up to 47 resistance genes, accurate prediction of resistance for 9 antibiotics
- Available now for Research Use Only (RUO)

Status:
- FDA 510(k) submitted May ‘19

Differentiators:
- Rapid AMR prediction
- CRE infection control

Coming Next:
- **Rapid urine test with sample-to-answer multiplex PCR from native specimen in <3 hours**
- **5 pathogen ID/quantitation, up to 47 resistance genes, and accurate prediction of resistance for 9 antibiotics**
- **Testing to support FDA *De Novo* submission in progress**

OpGen®

CURETIS' UNYVERO A30 *RQ* RAPID SAMPLE-TO-ANSWER TESTING PLATFORM

Platform open for partnering to rapidly create a broad menu of tests

First partnering agreement is anticipated to be negotiated in 2020

Key Design Features

- Fully integrated, closed, sample-to-answer MDx platform
- Universal real-time PCR technology for low- to mid-plex testing
- Flexible cartridge fluidics for numerous chemistries and assay formats
- Fast turn-around time of 45-90 minutes
- Light-weight, stackable benchtop design with small footprint
- Modular and scalable from 1 to 8 cartridge slots
- Designed for ease-of-use and flexible deployment in labs and near-patient settings
- Attractive COGS for instruments and reagents

Development Status

- First multiplex PCR successfully demonstrated on fully functional prototypes
- Manufacturing aspects fully specified and in development or implementation phase
- Curetis is aiming to have the the Unyvero A30 *RQ* platform ready for partnering in 2020

OpGen®

STRATEGIC BENEFITS

- Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection
- Proprietary molecular diagnostic tests and platforms
- Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics
- Global commercial channel capabilities & partners
- Financial leverage, operational synergies, and positive growth-driven business outlook

ARES GENETICS & ARESdb

Curetis' bioinformatics subsidiary with globally leading proprietary AI-powered knowledgebase for AMR informing PCR & NGS-based diagnostics

Global ARESdb Database

- Leading Knowledgebase on quantitative Antibiotic Resistance Markers building on **SIEMENS** Microbiology Strain Collection

Technology evaluation agreement with leading global IVD corporation

- Includes option to 3 month exclusive negotiation period for a license to ARESdb and ARES Technology Platform for human clinical diagnostic use

Bio-IT AMR agreement with QIAGEN

Pharma R&D agreement with Sandoz

NGS Service Laboratory

ACUITAS LIGHTHOUSE®: DIAGNOSTICS DATA MANAGEMENT PLATFORM FOR ANTIBIOTIC RESISTANT PATHOGENS†

Rapid molecular antibiotic resistance prediction



Acuitas Lighthouse®

OpGen®

Report Date: 07/25/2017 | Sample ID: 646547 | Test: Acuitas® AMR Gene Panel
Test Date: 07/25/2017 | Sample Type: Urine | Plate ID: P23894

Organisms Detected

Organism	Copies/mL
E. coli	Not Detected
E. faecalis	Not Detected
P. mirabilis	$>10^5$
K. pneumoniae	Not Detected
P. aeruginosa	Not Detected

Antibiotic Support

NO EVIDENCE OF RESISTANCE Predicted for:
Gentamicin, Tobramycin, Trimethoprim/Sulfonamide and Ceftazidime

RESISTANCE Predicted for:
Cefazolin, Cefepime, Cefotaxime, Ceftriaxone and Ampicillin

Antibiotic Resistance Genes Detected

Gene	Antibiotic class	Copies/mL
CTX-M-2	Cephalosporin	$> 10^5$
CTX-M-1	Cephalosporin	$> 10^5$

Comments:

1. Detection of multiple resistance genes in a polymicrobial specimen does not confirm which resistance marker is associated with the organism(s) detected. Subculturing and subsequent testing of the isolated organism is necessary to definitively link antimicrobial resistance with a specific organism.
2. Predictions are based on scenarios assuming the most resistant phenotype of organisms detected.

For Research Use Only. Not for use in diagnostic procedures. Antimicrobial resistance can occur via multiple mechanisms; the present test does not test for all applicable mechanisms for the antibiotics indicated. Therefore, failure to detect resistance genes does not necessarily infer antimicrobial susceptibility of the microorganisms present. In mixed cultures containing gram-negative bacteria and/or other microorganisms, the Acuitas AMR u5.47 test may not identify all the detectable microorganisms in a specimen. In rare instances, for specimens with microorganisms carrying a resistance marker, the Acuitas AMR u5.47 test may not yield a positive result for the resistance marker when the organism(s) are detected; subculture may be required for species identification and antimicrobial susceptibility testing of isolates.

Development contract for potential State-wide AMR surveillance network



Cloud-based bioinformatics platform powers our ability to rapidly generate meaningful results that have the potential to change the landscape of clinical management and improve outcomes for patients

†In development; For Research Use Only. Not for use in diagnostic procedures.

OpGen®

STRATEGIC BENEFITS

Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection

Proprietary molecular diagnostic tests and platforms

Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics

Global commercial channel capabilities & partners

Financial leverage, operational synergies, and positive growth-driven business outlook

COMMERCIAL STRATEGY

OpGen and Curetis to realize synergies from a combined commercial effort

- Multiple products to same hospital call points via same sales channel to drive synergies and cost efficiencies



Expanding global commercial reach though direct sales in U.S. and global distributors

> Direct sales in the U.S.

> European distribution through Menarini Diagnostics

> China distribution through Beijing Clear Biotech

> 18 distributors covering 43 countries in EU, ME, LATAM, and Asia

OpGen®

CURETIS PAN-EUROPEAN DISTRIBUTION BY MENARINI DIAGNOSTICS

Starting with 11 EU countries – option to expand relationship to further EMEA markets and additional product lines



Menarini Diagnostics Collaboration (Q1-2019)

> Covers entire Unyvero A50 product line

> Initial countries: **BE, CH, DE, ES, FR, IT, LU, NL, PT, SE, UK**

> Option to expand relationship to further EMEA countries

> Launch of collaboration at ECCMID 2019

A.MENARINI diagnostics

OpGen

STRATEGIC BENEFITS

- Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection
- Proprietary molecular diagnostic tests and platforms
- Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics
- Global commercial channel capabilities & partners
- Financial leverage, operational synergies, and positive growth-driven business outlook

FINANCIAL CONSIDERATIONS

- We anticipate combined company will be positioned for strong growth profile and sustained value creation
  - FY2018 revenues of $1.6 million (Curetis) and $2.9 million (OpGen)
  - Estimated FY2019 combined revenue of $5-6 million
  - Estimated 2020 combined revenue of $8-12 million

- Net loss from operations and cash burn anticipated to decrease starting in 2020 due to operating synergies from combined corporate, manufacturing & distribution, R&D, and sales & marketing organizations

- Transaction close contingent on completing interim equity financing as well as debt holder and shareholder approvals from both existing companies
  - ✓ OpGen has completed the interim equity financing
  - ✓ Debt holder approval obtained from EIB

OpGen®

EXPECTED COMBINED COMPANY GOVERNANCE TEAM

Combined team has decades of experience in precision medicine, molecular diagnostics and capital markets

Chairman of the Board:	William Rhodes
Chief Executive Officer:	Oliver Schacht, Ph.D.
Chief Financial Officer:	Timothy C. Dec
Board Members:	William Rhodes (Chairman) Evan Jones (Non-executive role) Three additional members selected by Curetis Two additional members selected by OpGen

POTENTIAL BUSINESS MILETONES

OpGen / Curetis Business Combination

- Successful shareholder votes and remaining debt holder approvals
- Closing of business combination transaction

Unyvero and Acuitas Rapid DNA tests

- FDA clearances and future FDA submissions
- LRT BAL launch in USA
- Unyvero A30 *RQ* partnering deal(s)
- China NMPA approval and launch for Unyvero HPN test

Ares Genetics

- Completion of Global IVD Corporation technology evaluation and licensing

Thank You!